NeoStem Reports Licensing of Treg Patents
September 16, 2013 at 07:35 AM EDT
NeoStem, Inc. (Nasdaq: NBS ) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced the licensing of three families of patents from the University of California, San Francisco ("UCSF"). NeoStem's worldwide exclusive license to these patents provides incremental protection for the Company's human Regulatory T cell ("Treg") platform, and